Porta C - Search Results

1

The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinoma.

Imarisio I, Paglino C, Ganini C, Magnani L, Caccialanza R, Porta C. Imarisio I, et al. Among authors: porta c. Future Oncol. 2012 Aug;8(8):1051-7. doi: 10.2217/fon.12.74. Future Oncol. 2012. PMID: 22894676

2

Weekly taxanes in metastatic breast cancer (review).

Zimatore M, Danova M, Vassallo E, Porta C, Macaluso MC, Schittone L, Riccardi A, Palmeri S. Zimatore M, et al. Among authors: porta c. Oncol Rep. 2002 Sep-Oct;9(5):1047-52. Oncol Rep. 2002. PMID: 12168071 Review.

3

Gemcitabine and oxaliplatin in the treatment of patients with immunotherapy-resistant advanced renal cell carcinoma: final results of a single-institution Phase II study.

Porta C, Zimatore M, Imarisio I, Natalizi A, Sartore-Bianchi A, Danova M, Riccardi A. Porta C, et al. Cancer. 2004 May 15;100(10):2132-8. doi: 10.1002/cncr.20226. Cancer. 2004. PMID: 15139055 Free article. Clinical Trial.

4

Low doses of subcutaneous interleukin-2 plus interferon-alpha do not induce thyroid function alterations in advanced renal cell carcinoma patients.

Sartore-Bianchi A, Soriani A, Mattioni R, Vaglio A, Buzio C, Porta C. Sartore-Bianchi A, et al. Among authors: porta c. Oncol Rep. 2004 Oct;12(4):855-9. Oncol Rep. 2004. PMID: 15375512

5

Pro-neoangiogenic cytokines (VEGF and bFGF) and anemia in solid tumor patients.

Porta C, Imarisio I, De Amici M, Bonomi L, Paglino C, Biscaldi E, Zimatore M, Sartore-Bianchi A, Danova M, Moratti R, Riccardi A. Porta C, et al. Oncol Rep. 2005 Apr;13(4):689-95. Oncol Rep. 2005. PMID: 15756443

6

Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients.

Porta C, Zimatore M, Bonomi L, Imarisio I, Paglino C, Sartore-Bianchi A, Mutti L. Porta C, et al. Lung Cancer. 2005 Jun;48(3):429-34. doi: 10.1016/j.lungcan.2004.11.015. Epub 2005 Jan 24. Lung Cancer. 2005. PMID: 15893013 Clinical Trial.

7

Maintenance biotherapy with interleukin-2 and interferon for metastatic renal cell cancer.

Porta C. Porta C. Expert Rev Anticancer Ther. 2006 Jan;6(1):141-52. doi: 10.1586/14737140.6.1.141. Expert Rev Anticancer Ther. 2006. PMID: 16375651 Review.

8

Sigmoid colon metastasis from sarcomatoid renal cell carcinoma.

Invernizzi R, Bencardino K, Porta C, Vercelli A, Viglio A, Manzoni M, Sagrada P, Danova M. Invernizzi R, et al. Among authors: porta c. Tumori. 2006 May-Jun;92(3):246-8. doi: 10.1177/030089160609200312. Tumori. 2006. PMID: 16869245

9

Renal cell carcinoma-induced immunosuppression: an immunophenotypic study of lymphocyte subpopulations and circulating dendritic cells.

Porta C, Bonomi L, Lillaz B, Paglino C, Rovati B, Imarisio I, Morbini P, Villa C, Danova M, Mensi M, Rovereto B. Porta C, et al. Anticancer Res. 2007 Jan-Feb;27(1A):165-73. Anticancer Res. 2007. PMID: 17352228 Free article.

10

Cytokine-based immunotherapy for advanced kidney cancer: past results and future perspectives in the era of molecularly targeted agents.

Porta C, Paglino C, Imarisio I, Bonomi L. Porta C, et al. ScientificWorldJournal. 2007 Apr 9;7:837-49. doi: 10.1100/tsw.2007.154. ScientificWorldJournal. 2007. PMID: 17619768 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

955 results

Search Page